Division of Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Division of Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Cell Stem Cell. 2021 May 6;28(5):833-845.e5. doi: 10.1016/j.stem.2020.12.015. Epub 2021 Jan 28.
Severe congenital neutropenia (SCN) is a life-threatening disorder most often caused by dominant mutations of ELANE that interfere with neutrophil maturation. We conducted a pooled CRISPR screen in human hematopoietic stem and progenitor cells (HSPCs) that correlated ELANE mutations with neutrophil maturation potential. Highly efficient gene editing of early exons elicited nonsense-mediated decay (NMD), overcame neutrophil maturation arrest in HSPCs from ELANE-mutant SCN patients, and produced normal hematopoietic engraftment function. Conversely, terminal exon frameshift alleles that mimic SCN-associated mutations escaped NMD, recapitulated neutrophil maturation arrest, and established an animal model of ELANE-mutant SCN. Surprisingly, only -1 frame insertions or deletions (indels) impeded neutrophil maturation, whereas -2 frame late exon indels repressed translation and supported neutrophil maturation. Gene editing of primary HSPCs allowed faithful identification of variant pathogenicity to clarify molecular mechanisms of disease and encourage a universal therapeutic approach to ELANE-mutant neutropenia, returning normal neutrophil production and preserving HSPC function.
严重先天性中性粒细胞减少症(SCN)是一种危及生命的疾病,通常由 ELANE 的显性突变引起,这些突变干扰了中性粒细胞的成熟。我们在人类造血干细胞和祖细胞(HSPCs)中进行了 CRISPR pooled 筛选,将 ELANE 突变与中性粒细胞成熟潜能相关联。早期外显子的高效基因编辑引发了无意义介导的衰变(NMD),克服了 ELANE 突变 SCN 患者 HSPCs 中的中性粒细胞成熟阻滞,并产生了正常的造血植入功能。相反,模拟 SCN 相关突变的末端外显子移码等位基因逃避了 NMD,重现了中性粒细胞成熟阻滞,并建立了 ELANE 突变 SCN 的动物模型。令人惊讶的是,只有 -1 框插入或缺失(indels)阻碍了中性粒细胞的成熟,而 -2 框晚期外显子 indels 抑制了翻译并支持中性粒细胞的成熟。对原发性 HSPCs 的基因编辑允许对变异的致病性进行准确鉴定,以阐明疾病的分子机制,并鼓励对 ELANE 突变性中性粒细胞减少症采用普遍的治疗方法,恢复正常的中性粒细胞生成并保持 HSPC 功能。